Anzeige
Mehr »
Dienstag, 25.11.2025 - Börsentäglich über 12.000 News
Goldrausch 2.0: 60% Insideranteil - warum dieser Gold-Explorer als Geheimtipp gilt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40DEH | ISIN: US09073Q3039 | Ticker-Symbol: 2F5
Frankfurt
25.11.25 | 15:29
0,745 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SCINAI IMMUNOTHERAPEUTICS LTD ADR Chart 1 Jahr
5-Tage-Chart
SCINAI IMMUNOTHERAPEUTICS LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,7900,83022:12
0,7850,83522:00

Aktuelle News zur SCINAI IMMUNOTHERAPEUTICS LTD Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SCINAI IMMUNOTHERAPEUTICS LTD Aktie jetzt für 0€ handeln
13.11.Scinai Immunotherapeutics beraumt jährliche Hauptversammlung für 22. Dezember an2
13.11.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer-
12.11.Scinai Immunotherapeutics Ltd. - S-8, Securities to be offered to employees in employee benefit plans-
06.10.Scinai receives $246,000 grant to expand biotech manufacturing4
06.10.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
22.09.Scinai Immunotherapeutics Ltd. - F-1, Registration statement for certain foreign private issuers2
22.09.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer-
11.09.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
02.09.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer2
02.09.Scinai Immunotherapeutics Ltd.: Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet302JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing...
► Artikel lesen
29.07.Scinai Immunotherapeutics stock soars on promising skin disease drug data8
12.06.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer3
05.06.Scinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.138The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing...
► Artikel lesen
02.06.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
30.05.Scinai Immunotherapeutics reports Q1 results1
30.05.Scinai Immunotherapeutics Ltd.: Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn260JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on...
► Artikel lesen
07.05.Scinai Immunotherapeutics Ltd.: Scinai Announces Annual Financial Results for 2024113JERUSALEM, May 7, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing...
► Artikel lesen
27.03.Scinai Immunotherapeutics Ltd.: Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions142Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1